The CLIP1–LTK fusion is an oncogenic driver in non‐small‐cell lung cancer
5 (531) · $ 21.50 · In stock
Clinical application of the AMOY 9-in-1 panel to lung cancer patients - ScienceDirect
IJMS, Free Full-Text
医药前沿nature发文：CLIP1-LTK 融合基因-非小细胞肺癌的新治疗靶点医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
IJMS, Free Full-Text
The CLIP1–LTK fusion is an oncogenic driver in non‐small‐cell lung cancer
Genotype-phenotype mapping of a patient-derived lung cancer organoid biobank identifies NKX2-1-defined Wnt dependency in lung adenocarcinoma - ScienceDirect
Novel mutations in a second primary gastric cancer in a patient treated for primary colon cancer, World Journal of Surgical Oncology
Frontiers Anaplastic lymphoma kinase inhibitors—a review of anticancer properties, clinical efficacy, and resistance mechanisms
Frontiers Cancer/Testis Antigens as Biomarker and Target for the Diagnosis, Prognosis, and Therapy of Lung Cancer
The CLIP1-LTK fusion is an oncogenic driver in non-small-cell lung cancer. - Abstract - Europe PMC
AMG-510 and cisplatin combination increases antitumor effect in lung adenocarcinoma with mutation of KRAS G12C: a preclinical and translational research
media.springer/m685/springer-static/imag
